识别继发性髓外多发性骨髓瘤发生高危患者
该研究基于捷克共和国2005至2017年诊断的4985例多发性骨髓瘤患者,分析其中234例继发性髓外多发性骨髓瘤患者,以明确继发性髓外多发性骨髓瘤发生的危险因素。研究发现诊断时年龄小于65岁、高乳酸脱氢酶水平、广泛溶骨性活动、IgA型或非分泌型多发性骨髓瘤是主要危险因素;后续发生髓外多发性骨髓瘤的新诊断患者无进展生存和总生存均更差。
要点
- 诊断时年龄<65岁、LDH>5 μkat/l、广泛溶骨活动、IgA型或非分泌型MM是继发性EMD的主要危险因素。
- 后续发生EMD的新诊断MM患者中位PFS为13.8个月,无未来EMD者为18.8个月。
- 后续发生EMD的新诊断MM患者中位OS为26.7个月,无未来EMD者为58.7个月。
核心结论
- 具有继发性EMD相关特定危险因素的新诊断MM患者在继发性EMD发生前疾病病程更具侵袭性。
研究设计与样本
- 研究分析了捷克共和国2005至2017年诊断的4985例MM患者中的234例继发性EMD患者,以明确继发性EMD发生的危险因素。
主要发现
- 诊断时年龄<65岁者继发性EMD发生风险升高(OR 4.38,95%CI:2.46-7.80,P<0.0001)。
- 诊断时LDH>5 μkat/l者继发性EMD发生风险升高(OR 2.07,95%CI:1.51-2.84,P<0.0001)。
- 诊断时广泛溶骨性活动者继发性EMD发生风险升高(OR 2.21,95%CI:1.54-3.15,P<0.001)。
- 诊断时IgA型MM者继发性EMD发生风险升高(OR 1.53,95%CI:1.11-2.11,P=0.009),非分泌型MM者风险亦升高(OR 2.83,95%CI:1.32-6.04,P=0.007)。
- 后续发生EMD的新诊断MM患者较无未来EMD者中位PFS更短(13.8个月,95%CI:11.4-16.3 vs 18.8个月,95%CI:17.7-19.9,P=0.006),中位OS亦更短(26.7个月,95%CI:18.1-35.4 vs 58.7个月,95%CI:54.8-62.6,P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is characterized by malignant plasma cell infiltration of the bone marrow. In extramedullary multiple myeloma (EMD), a subclone of these cells migrates out of the bone marrow. Out of 4 985 MM patients diagnosed between 2005 and 2017 in the Czech Republic, we analyzed 234 secondary EMD patients to clarify risk factors of secondary EMD development. We found younger age [<65 years; odds ratio (OR) 4·38, 95% confidence interval (CI): 2·46-7·80, P < 0·0001], high lactate dehydrogenase (LDH) levels (>5 μkat/l; OR 2·07, 95% CI: 1·51-2·84, P < 0·0001), extensive osteolytic activity (OR 2·21, 95% CI: 1·54-3·15, P < 0·001), and immunoglobulin A (IgA; OR 1·53, 95% CI: 1·11-2·11, P = 0·009) or the non-secretory type of MM (OR 2·83; 95% CI: 1·32-6·04, P = 0·007) at the time of MM diagnosis to be the main risk factors for secondary EMD development. Newly diagnosed MM (NDMM) patients with subsequent EMD had inferior median progression-free (PFS) and overall (OS) survival when compared to NDMM patients without future EMD [mPFS: 13·8 months (95% CI: 11·4-16·3) vs 18·8 months (95% CI: 17·7-19·9), P = 0·006; mOS: 26·7 months (95% CI: 18·1-35·4) vs 58·7 months (95% CI: 54·8-62·6), P < 0·001]. We found that NDMM patients with specific risk factors associated with secondary EMD development have a more aggressive disease course before secondary EMD develops.
引用
- Stork M, Sevcikova S, Minarik J, et al. Identification of patients at high risk of secondary extramedullary multiple myeloma development. Br J Haematol. 2021. PMID: 34726261. doi:10.1111/bjh.17925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。